Supernus Pharmaceuticals Stock Analysis
SUPN Stock | USD 34.11 0.37 1.10% |
Supernus Pharmaceuticals is undervalued with Real Value of 37.42 and Target Price of 42.25. The main objective of Supernus Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Supernus Pharmaceuticals is worth, separate from its market price. There are two main types of Supernus Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Supernus Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Supernus Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Supernus Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Supernus Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Supernus Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Supernus Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Supernus |
Supernus Stock Analysis Notes
About 95.0% of the company shares are owned by institutional investors. The book value of Supernus Pharmaceuticals was at this time reported as 16.84. The company has Price/Earnings To Growth (PEG) ratio of 1.47. Supernus Pharmaceuticals had not issued any dividends in recent years. Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company was incorporated in 2005 and is headquartered in Rockville, Maryland. Supernus Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 603 people. To find out more about Supernus Pharmaceuticals contact Jack Khattar at 301 838 2500 or learn more at https://www.supernus.com.Supernus Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Supernus Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Supernus Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company currently holds 41.53 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Supernus Pharmaceuticals has a current ratio of 0.83, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Supernus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Supernus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Supernus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Supernus to invest in growth at high rates of return. When we think about Supernus Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
Over 95.0% of Supernus Pharmaceuticals shares are owned by institutional investors | |
Latest headline from news.google.com: Supernus Pharmaceuticals, Inc. VP Padmanabh P. Bhatt Sells 14491 Shares of Stock - Defense World |
Supernus Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Supernus Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Supernus Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Supernus Largest EPS Surprises
Earnings surprises can significantly impact Supernus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2016-05-03 | 2016-03-31 | 0.09 | 0.08 | -0.01 | 11 | ||
2015-08-04 | 2015-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2017-05-09 | 2017-03-31 | 0.22 | 0.19 | -0.03 | 13 |
Supernus Pharmaceuticals Thematic Classifications
In addition to having Supernus Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Obamacare RepealLarge healthcare related equities associated with Obamacare | ||
Trump EquitiesCompanies that have responded positively to Trump presidency |
Supernus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Supernus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Supernus Pharmaceuticals backward and forwards among themselves. Supernus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Supernus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Geode Capital Management, Llc | 2023-12-31 | 1.2 M | Aristotle Capital Boston, Llc | 2023-12-31 | 1.2 M | Pictet Asset Manangement Sa | 2023-12-31 | 1 M | Congress Asset Management Company, Llp | 2023-12-31 | 920.8 K | Ashford Capital Management Inc | 2023-12-31 | 826.5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 723.4 K | Victory Capital Management Inc. | 2023-12-31 | 690.4 K | Northern Trust Corp | 2023-12-31 | 648.4 K | Ameriprise Financial Inc | 2023-12-31 | 559.7 K | Blackrock Inc | 2023-12-31 | 10.4 M | Vanguard Group Inc | 2023-12-31 | 6.2 M |
Supernus Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.87 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Supernus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Supernus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Supernus Profitablity
Supernus Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Supernus Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Supernus Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Supernus Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Supernus Pharmaceuticals' profitability requires more research than a typical breakdown of Supernus Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.01 | 0.01 | |
Return On Assets | 0.0009 | 0.001 | |
Return On Equity | 0 | 0 |
Management Efficiency
At this time, Supernus Pharmaceuticals' Return On Capital Employed is very stable compared to the past year. As of the 29th of March 2024, Return On Assets is likely to grow to 0.001, while Return On Equity is likely to drop 0. At this time, Supernus Pharmaceuticals' Return On Assets are very stable compared to the past year. Supernus Pharmaceuticals' management efficiency ratios could be used to measure how well Supernus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Last Reported | Projected for 2024 | ||
Price Book Value Ratio | 1.71 | 1.53 | |
Enterprise Value Multiple | 15.72 | 8.38 | |
Price Fair Value | 1.71 | 1.53 |
The analysis of Supernus Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Supernus Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Supernus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.972 |
Technical Drivers
As of the 29th of March, Supernus Pharmaceuticals has the Semi Deviation of 2.18, coefficient of variation of 912.01, and Risk Adjusted Performance of 0.0686. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Supernus Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Supernus Pharmaceuticals, which can be compared to its competition. Please validate Supernus Pharmaceuticals variance and potential upside to decide if Supernus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 34.11 per share. Given that Supernus Pharmaceuticals has jensen alpha of 0.0165, we advise you to double-check Supernus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.Supernus Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Supernus Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Supernus Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Supernus Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Supernus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Supernus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Supernus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Padmanabh Bhatt over a week ago Disposition of 14491 shares by Padmanabh Bhatt of Supernus Pharmaceuticals at 35.31 subject to Rule 16b-3 | ||
Padmanabh Bhatt over two weeks ago Disposition of 3884 shares by Padmanabh Bhatt of Supernus Pharmaceuticals at 32.99 subject to Rule 16b-3 | ||
Tami Martin over a month ago Disposition of 1250 shares by Tami Martin of Supernus Pharmaceuticals subject to Rule 16b-3 | ||
Victor Vaughn over a year ago Exercise or conversion by Victor Vaughn of 9250 shares of Supernus Pharmaceuticals subject to Rule 16b-3 | ||
John Siebert over a year ago Supernus Pharmaceuticals exotic insider transaction detected | ||
John Siebert over a year ago Acquisition by John Siebert of 3882 shares of Supernus Pharmaceuticals subject to Rule 16b-3 |
Supernus Pharmaceuticals Predictive Daily Indicators
Supernus Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Supernus Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Supernus Pharmaceuticals Corporate Filings
F4 | 25th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 22nd of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 21st of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 15th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 14th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 29th of February 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 28th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 27th of February 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Supernus Pharmaceuticals Forecast Models
Supernus Pharmaceuticals' time-series forecasting models are one of many Supernus Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Supernus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Supernus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Supernus Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Supernus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Supernus Pharmaceuticals. By using and applying Supernus Stock analysis, traders can create a robust methodology for identifying Supernus entry and exit points for their positions.
Last Reported | Projected for 2024 | ||
Pretax Profit Margin | 0 | 0 | |
Operating Profit Margin | 0.02 | 0.02 | |
Net Profit Margin | 0 | 0 | |
Gross Profit Margin | 0.72 | 0.69 |
Current Supernus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Supernus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Supernus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
42.25 | Strong Buy | 4 | Odds |
Most Supernus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Supernus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Supernus Pharmaceuticals, talking to its executives and customers, or listening to Supernus conference calls.
Supernus Stock Analysis Indicators
Supernus Pharmaceuticals stock analysis indicators help investors evaluate how Supernus Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Supernus Pharmaceuticals shares will generate the highest return on investment. By understating and applying Supernus Pharmaceuticals stock analysis, traders can identify Supernus Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 93.1 M | |
Common Stock Shares Outstanding | 55.5 M | |
Total Stockholder Equity | 921.5 M | |
Tax Provision | 11.3 M | |
Quarterly Earnings Growth Y O Y | -0.959 | |
Property Plant And Equipment Net | 42.5 M | |
Cash And Short Term Investments | 254.9 M | |
Cash | 75.1 M | |
Accounts Payable | 2 M | |
Net Debt | -33.5 M | |
50 Day M A | 30.177 | |
Total Current Liabilities | 290.2 M | |
Other Operating Expenses | 594.1 M | |
Non Current Assets Total | 915.9 M | |
Forward Price Earnings | 20.1613 | |
Non Currrent Assets Other | 8.5 M | |
Stock Based Compensation | 26.8 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.